Navigation Links
Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
Date:8/27/2007

First patient treated in trial of prGCD treatment of Gaucher Disease

CARMIEL, Israel, Aug. 27 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX), today announced that it has treated the first patient in its phase III clinical trial of the Company's lead product candidate, prGCD, a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD) for the treatment of Gaucher disease, a lysosomal storage disorder in humans.

The phase III clinical trial will take place in centers in the United States, Israel and other locations worldwide. Professor Ari Zimran, Director of the Gaucher Clinic at Shaare Zedek Medical Center in Jerusalem, Israel, will serve as principal investigator for the trial. The trial design consists of 30 male and female patients with Gaucher disease in a randomized, double- blind, dose ranging study, with two parallel groups.

Dr. David Aviezer, President and CEO of Protalix, stated, "Enrolling our first patients in this phase III clinical trial represents a significant milestone as we work toward our goal of commercializing prGCD, our proprietary treatment for Gaucher disease. After extensive research from the committed members of our team, we believe that we have developed a treatment that will not only be effective, but also safe and cost efficient when compared to current treatment options. We look forward to monitoring the progress of our trial and the potential benefits for our participating patients."

Professor Ari Zimran added, "With the treatment of the first patient in the phase III clinical trial, we are one step closer to providing another treatment option for those who suffer from Gaucher disease. Progress to date has been very e
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
2. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
3. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
4. Newest Adult Stem Therapy Treats Diabetes
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
9. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
10. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
11. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  Alere Inc. (NYSE: ... the following statement today in support of President ... "As the global leader in rapid diagnostics for ... national strategy to address the serious threat of antibiotic ... the Administration on initiatives to promote the development of ...
(Date:9/19/2014)... ORLANDO, Fla. , Sept. 19, 2014 /PRNewswire/ ... to grow, with the publication of two papers this ... Otolaryngology – Head and Neck Surgery , ... both objective and subjective measures of sleep disordered breathing, ... for the reduction in obstructive sleep apnea severity and ...
(Date:9/19/2014)... , Sept. 19, 2014  CytRx Corporation (Nasdaq: ... company specializing in oncology, today announced that David ... at BioCentury,s 2014 NewsMakers in the Biotech Industry Conference on ... Time. The conference will take place at the Millennium ... . A live and archived webcast of ...
Breaking Medicine Technology:Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3
... MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today ... conferences in September: Stifel Nicolaus Healthcare Conference Thursday, ... UBS Global Life Sciences Conference Wednesday, September 21, at 9:30 ... of each event will be available on the Investor Relations ...
... Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS), today ... presenting at two upcoming investor conferences taking place in New ... will present at the Rodman and Renshaw Annual Global Investment ... On Wednesday, September 14, Mr. Shortall will present at the ...
Cached Medicine Technology:Unilife to Participate in Two Investor Conferences 2
(Date:9/20/2014)... 2014 "As a nurse, patients always ask ... an inventor from Tamaqua, Pa. "The reason that they cannot ... of their chairs. My invention enables them to check oxygen ... Sensor to make it easier to monitor the contents of ... when the tank is low. It allows changeovers to be ...
(Date:9/20/2014)... September 20, 2014 QueenBeeTickets.com is ready ... star’s tour performances. She will visit many cities in ... until the 16th of April. , Click Here ... Tour tickets at QueenBeeTickets.com. , The star’s fans are ... see their favorite young singer in a live performance. ...
(Date:9/20/2014)... The first federal bellwether trial of a DePuy ... in the U.S. District Court, Northern District of Texas, ... the week opened in the DePuy Pinnacle Hip ... vice president, who discussed the clinical testing performed on ... According to Reuters, the executive stated that the Pinnacle ...
(Date:9/19/2014)... 2014 Nearly 780 Risperdal lawsuits are ... where a meeting took place to discuss the next ... in the court’s mass tort program. Attorneys for the ... week at the Complex Litigation Center in Philadelphia’s City ... proceedings. The Risperdal lawsuits filed against Johnson & Johnson ...
(Date:9/19/2014)... City, KS (PRWEB) September 19, 2014 ... is responding to families in regions of the Philippines being ... , More than 1,060 families evacuated to the nearest ... storm Fung-Wong brought heavy rain and gusty winds to portions ... Friday causing heavy flooding. Some homes filled with more than ...
Breaking Medicine News(10 mins):Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 3Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 4Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2
... Maureen Salamon HealthDay Reporter , TUESDAY, Aug. ... investigating injectable drugs to treat psoriasis -- an autoimmune ... medications are not linked to higher heart risks. ... information from drug makers impeded their ability to assess ...
... bowel disease (IBD), which affects more than 1 million ... response triggered by environmental factors, such as bacteria, in ... inflammation of the lining of the colon, is one ... IBD is prompted by different cytokines small signaling ...
... Reporter , TUESDAY, Aug. 23 (HealthDay News) -- A test ... are most likely to raise the risk of invasive cervical ... accurate for many women than the Pap test alone, a ... HPV-positive, using the HPV test alone appears to be enough, ...
... are to investigate whether the therapeutic effects of clay ... of anger, anxiety and depression. Academics are teaming ... gallery and local artists for the innovative project that ... offer to young people struggling with mental health problems. ...
... psychology department show that people who use more ... are viewed more negatively than those who use milder ... adults are more negative about using anti-aging methods than ... rapid growth of the anti-aging cosmetic industry, age concealment ...
... drug and mental disorders would benefit greatly from smoking ... be five times more successful at kicking the habit, ... Center has found. Smokers with these comorbid conditions ... have a more difficult time quitting and represent a ...
Cached Medicine News:Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 2Health News:Injectable Psoriasis Drugs May Not Hike Heart Risks: Study 3Health News:Novel cytokine protects mice from colitis 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 2Health News:HPV Test Might Be Better Predictor of Cervical Cancer Than Pap Smear 3Health News:Modelling emotions: A potential new therapy for disturbed teenagers 2Health News:Modelling emotions: A potential new therapy for disturbed teenagers 3Health News:U of T research shows anti-aging techniques not yet viewed as acceptable 2Health News:Smokers with comorbid conditions need help from their doctor to quit 2Health News:Smokers with comorbid conditions need help from their doctor to quit 3
... a sterile, nonpyrogenic, viscoelastic preparation of ... weight fraction of sodium hyaluronate., ,Healon ... dissolved in physiological sodium chloride phosphate ... weight polymer is made up of ...
... DUOVISC Viscoelastic System is designed to ... properties that can be used differently and ... cataract procedure. The choice of the viscoelastic ... differential ability of each to facilitate performance ...
... fiscal year 2004, Biomet plans to ... to the global market, enhancing visualization ... Acumen technology was developed in conjunction ... based in Hollywood, Florida. Procedure-specific software ...
... in awhile, a product comes along that ... in its category. The new StealthStation TREON ... a product. Built on the phenomenal success ... surgical navigation system in the worldthe new ...
Medicine Products: